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It is 3 years since the Food and Drug Administration approved
high-dose interferon a-2b for the adjuvant treatment of resected
melanoma at high risk of recurrence (American Joint Committee
on Cancer stages IIB and III). The enthusiastic response to the
results of the Eastern Co-operative Oncology Group (ECOG) 1684
trial in the USA has not been replicated in Europe. Although the
study was the first to show a significant improvement in relapse-
free and overall survival with an adjuvant treatment many oncolo-
gists have not been prepared to submit patients to such an arduous
regimen without confirmatory trials. Ravaud et al (1999) confirm
the toxicity reported by the ECOG 1684 investigators, with 50%
and 47% of their patients experiencing a grade 3 or 4 toxicity
during the induction and consolidation phases of high-dose inter-
feron therapy respectively. Only two-thirds of the patients received
at least 80% of the intended dose. They conclude that the
‘Kirkwood’ regimen cannot be accepted as standard therapy
without confirmation from Intergroup study 1690 of the earlier
results (Kirkwood et al, 1996).
The Intergroup trial, of high-dose interferon (as in ECOG 1684)
versus low-dose interferon (3 Mu thrice weekly) versus observa-
tion, was recently unblinded and preliminary results were
presented at the ASCO congress in Atlanta. Unfortunately they do
little to help resolve the issues surrounding the adjuvant therapy of
melanoma. Although the improvement in relapse-free survival
with high-dose treatment seen in the ECOG 1684 trial is
confirmed (P = 0.05; hazard ratio 1.28) there was no significant
improvement in overall survival. A smaller benefit in relapse-free
survival, which was not statistically significant, was seen in the
low-dose arm (P = 0.17; hazard ratio 1.09). Pooling the results of
the two studies shows an improvement in relapse-free survival
(P = 0.0021; hazard ratio 1.34) but not in overall survival
(P = 0.21; hazard ratio 1.13) for high-dose treatment.
This unexpected difference in the results of the two studies can
be explained by an improvement in the outcome of those patients
kept under observation. This was largely due to an increase in
survival after relapse in patients under observation in the
Intergroup trial (4.4 years vs 1.8 years for this group in ECOG
1684). This may be due to changes in staging and surgical tech-
niques: for example, sentinel-node mapping has altered the stage
III population, with many patients now exhibiting only micro-
scopic disease. In the earlier trial, significant differences in overall
survival were only seen amongst patients with clinically apparent
lymphadenopathy prior to resection. There was only a trend
towards improved survival in the (small) group of patients with
clinically inapparent, but microscopically detected, lymph node
involvement. It remains to be seen how interferon affects the
outcome in these patients, if at all. An increase in the proportion of
patients with only microscopic disease might explain the different
conclusions, to date, of the ECOG and Intergroup trials.
Alternatively, some observation arm patients crossed over to inter-
feron at first relapse and this may have had an impact. Thirty eight
of 121 observation patients who relapsed in the Intergroup Study
were treated with interferon. These patients survived significantly
longer than their counterparts who did not receive the drug (2.22
years vs 0.82 years; P = 0.0021). Although providing further
evidence that interferon has activity against melanome, this raises
the question of when it is best given to patients.
Given the Intergroup result, the use of low-dose adjuvant inter-
feron may not be rewarding. Neither the Intergroup trial nor the
earlier World Health Organization study 16 have shown any
benefit in terms of either relapse-free or overall survival for this
approach (Cascinu, 1995). Further data on this dose of interferon
will be available when the United Kingdom Central Committee for
Cancer Research ‘AIMHIGH’ trial reports.
There seems little doubt that high-dose interferon has an impact
on melanoma, and can delay the time to relapse in high-risk
melanoma patients. Both the ECOG and Intergroup studies indicate
this, and there was a similar trend in a smaller North Central Cancer
Treatment Group high dose study (Creagan et al, 1995). However,
around four-fifths of patients treated with high-dose interferon
experience moderate or severe toxicity. Since we do not know the
mechanism by which interferon acts against melanoma, further
work is required to establish which patients benefit from which
dose and schedule of interferon. The final report of the Intergroup
study will address this in part, since measures of effect on periph-
eral blood lymphocyte cytotoxicity form part of the study.
For now, is not possible to recommend high-dose interferon as
standard adjuvant treatment for melanoma: the toxicity of the
regimen demands a clear improvement in overall survival to
justify its use. Patients with resected lymph node involvement
should be advised of the results of the ECOG 1684 and Intergroup
studies, so that they may come to an informed decision about adju-
vant treatment of their melanoma. Meanwhile, future studies of
adjuvant therapy in melanoma should include observation as their
control arm.
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